Heart drug mavacamten under the microscope in Real-World patient study
NCT ID NCT07557498
First seen May 04, 2026 · Last updated May 16, 2026 · Updated 2 times
Summary
This study is tracking 362 adults with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle thickens and blocks blood flow) who are taking the drug mavacamten in regular U.S. clinics. Researchers want to see how the drug affects blood pressure, heart function, and daily life, and also interview doctors about their experiences. The goal is to learn how well mavacamten works outside of controlled trials, not to test a new cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Adelphi Real World
RECRUITINGBollington, Macclesfield, SK10 5JB, United Kingdom
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.